All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Shiga toxin (Stx) is the major virulence factor of enterohemorrhagic *Escherichia coli* (EHEC). EHEC are non-invasive bacteria \[[@ppat.1004619.ref001]\] causing gastrointestinal infection presenting with diarrhea, hemorrhagic colitis and in severe cases leading to hemolytic uremic syndrome (HUS) characterized by thrombocytopenia, microangiopathic hemolytic anemia and acute renal failure. The renal cortical lesions affect both glomeruli and tubuli. In glomeruli the lesion is termed thrombotic microangiopathy presenting with glomerular capillary endothelial cell damage and formation of microthrombi \[[@ppat.1004619.ref002]\]. In tubuli extensive apoptosis has been described \[[@ppat.1004619.ref003]\]. The tubular damage can be reproduced in mouse models after infection with EHEC \[[@ppat.1004619.ref004]--[@ppat.1004619.ref006]\] or intraperitoneal injection of Stx2 and lipopolysaccharide (LPS) \[[@ppat.1004619.ref007]\]. Mice orally infected with EHEC develop systemic and neurological symptoms 7--8 days after inoculation \[[@ppat.1004619.ref008]\] with extensive intestinal and renal pathology, the latter with fibrinogen deposition in glomeruli, as well as marked apoptosis of both tubular and glomerular cells \[[@ppat.1004619.ref003],[@ppat.1004619.ref006],[@ppat.1004619.ref008],[@ppat.1004619.ref009]\]. Laboratory investigation demonstrated fragmented red blood cells, thrombocytopenia and elevated creatinine \[[@ppat.1004619.ref005],[@ppat.1004619.ref008]\]. Thus EHEC-infected mice exhibit clinical and pathological findings that mimic certain aspects of human infection and HUS. Using isogenic strains of *E. coli* O157:H7 these findings were most specifically attributed to the strain's production of Stx \[[@ppat.1004619.ref008]\].

In order for cells to be affected by Stx, the toxin needs to first bind to its receptor, globotriaosylceramide (Gb3) \[[@ppat.1004619.ref010]\] via its B-binding subunits, followed by endocytosis of the holotoxin. Intracellularly toxin is transported to the endoplasmic reticulum \[[@ppat.1004619.ref011]\] where the A-subunit binds to ribosomes and cleaves an adenine base from 28S rRNA of the 60S ribosomal subunit \[[@ppat.1004619.ref012]\], thus inhibiting protein synthesis. The presence of a glycolipid receptor capable of binding Stx has been considered essential for predicting which cells the toxin will affect \[[@ppat.1004619.ref013]--[@ppat.1004619.ref016]\]. However, human intestinal cells may be damaged by Stx even in the absence of the toxin receptor \[[@ppat.1004619.ref017]\] and murine glomeruli, lacking the Gb3 receptor, develop toxin-related injury in vivo \[[@ppat.1004619.ref018]--[@ppat.1004619.ref020]\]. These findings suggest that Stx may also mediate cytotoxicity to target organ cells in a Gb3 receptor-independent manner.

The means by which Stx affects target organ cells has not been clarified. Negligible amounts of free toxin are present in the circulation during HUS \[[@ppat.1004619.ref021]\]. The toxin circulates preferentially in cell-bound form, mainly bound to platelets, neutrophils and monocytes \[[@ppat.1004619.ref022],[@ppat.1004619.ref023]\]. In order to affect renal cells the toxin would first have to be released from blood cells possibly due to higher affinity for renal endothelial cells \[[@ppat.1004619.ref024],[@ppat.1004619.ref025]\]. A prerequisite for this to occur would be that the toxin remains on the cell membrane and does not undergo receptor-mediated endocytosis. Evidence has, however, shown that the toxin does undergo endocytosis in platelets \[[@ppat.1004619.ref026]\]. Furthermore, stimulation of blood cells with Stx leads to the release of platelet and leukocyte-derived microvesicles \[[@ppat.1004619.ref022],[@ppat.1004619.ref027]\] with surface-bound tissue factor \[[@ppat.1004619.ref022]\] as well as C3 and C9 deposition \[[@ppat.1004619.ref027]\], contributing to a pro-thrombotic state.

Microvesicles are small (\<1 μm), pro-inflammatory vesicles shed by host cells during activation and apoptosis. They contain surface markers of their parent cells \[[@ppat.1004619.ref028],[@ppat.1004619.ref029]\]. Microvesicles mediate cell-to-cell communication by transferring cell surface receptors \[[@ppat.1004619.ref030],[@ppat.1004619.ref031]\], chemokines \[[@ppat.1004619.ref032]\], mRNAs \[[@ppat.1004619.ref033]\] and microRNAs \[[@ppat.1004619.ref034]\] from the cell of origin to target cells. They circulate in elevated levels during EHEC-associated HUS \[[@ppat.1004619.ref022],[@ppat.1004619.ref027],[@ppat.1004619.ref035]\].

In this study we investigated the possibility that blood cell-derived microvesicles contain Stx that is thus transferred into target organ cells and if Stx within microvesicles retains cytotoxic potential. We found Stx within blood cell-derived microvesicles in the circulation of patients with HUS and of mice infected with *E. coli* O157:H7, and within human and murine renal tissue. In vitro studies showed that human blood cell-derived microvesicles containing Stx underwent endocytosis in human glomerular endothelial cells where microvesicles released the toxin and lead to cell death by inhibition of protein synthesis. Bacterial toxin can thus be transferred within host cell-derived microvesicles and evade the host response.

Results {#sec002}
=======

Patients with HUS have circulating microvesicles containing Stx2 {#sec003}
----------------------------------------------------------------

High levels of platelet and leukocyte-derived microvesicles were detected in plasma from patients with HUS (n = 13, Patients 1--13 in [S1 Table](#ppat.1004619.s001){ref-type="supplementary-material"}, supporting information) by flow cytometry ([Table 1](#ppat.1004619.t001){ref-type="table"}). Most of the microvesicles were of platelet origin. Similarly, red blood cell (RBC)-derived microvesicles were detected in plasma from patients with HUS (n = 6, Patients 6--11).

10.1371/journal.ppat.1004619.t001

###### Numbers and cellular origin of microvesicles containing Stx2 in plasma from patients and controls.

![](ppat.1004619.t001){#ppat.1004619.t001g}

                                                                     Platelet-derived microvesicles (x10^3^/mL)   Monocyte-derived microvesicles (x10^3^/mL)         Neutrophil-derived microvesicles (x10^3^/mL)   RBC-derived microvesicles (x10^3^/mL)                                                                                                                                              
  ------------------------------------------------------------------ -------------------------------------------- -------------------------------------------------- ---------------------------------------------- ------------------------------------------------- ---------------------- ------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------
  **HUS Acute phase (n = 13)**                                       1697 (315--3900)\*\*\*                       453 (57--855)\*\*\*                                603 (99--1509)\*\*                             187 (30--354)\*\*                                 517 (45--1794)\*\*\*   135 (38--222)\*\*\*                               543 (240--1182)[^a^](#t001fn002){ref-type="table-fn"}   51 (12--120)\*[^a^](#t001fn002){ref-type="table-fn"}
  **Recovery (n = 12)**                                              154 (63--241)                                0                                                  43 (6--212)                                    0                                                 13 (3--91)             0                                                 114 (90--618)[^b^](#t001fn003){ref-type="table-fn"}     0[^b^](#t001fn003){ref-type="table-fn"}
  **HC (n = 5)**                                                     215 (108--574)                               0 (0--212)[^c^](#t001fn004){ref-type="table-fn"}   102 (35--489)                                  0 (0--99)[^c^](#t001fn004){ref-type="table-fn"}   94 (25--324)           0 (0--72)[^c^](#t001fn004){ref-type="table-fn"}   NA                                                      NA
  **Controls (n = 10)** [^**d**^](#t001fn005){ref-type="table-fn"}   123 (80--171)                                0                                                  42 (21--56)                                    0                                                 28 (15--38)            0                                                 5 (0--8)                                                0
  **Renal failure controls (n = 2)**                                 130--282                                     0                                                  31--96                                         0                                                 58--133                0                                                 NA                                                      NA

Samples from pediatric HUS patients (1--12) were available during the acute phase of disease and after recovery whereas samples from patient 13 and patients with hemorrhagic colitis (15--19) were only available during the acute phase of disease. Data are expressed as median and (range) of circulating microvesicles positive for each membrane specific marker (CD42b for platelets, CD38 for monocytes and CD66 for neutrophils). \*\*\* Denotes *P* value \<0.001, \*\* *P*\<0.01 and \**P*\<0.05 when comparing microvesicles in plasma from HUS patients with recovery.

^a^, HUS patients analyzed for CD235a-positive red blood cells (RBC)-derived microvesicles (n = 6, not all patients were analyzed). Significantly higher levels were detected during the acute phase compared to controls (n = 6), *P*\<0.001).

^b^, Recovery samples analyzed for RBC-derived microvesicles (n = 3).

^c^, Two of the patients with HC had detectable levels of microvesicles containing Stx2.

^d^, Pediatric controls (n = 4) analyzed for platelet (CD42b), monocyte (CD38) and neutrophil (CD66)-derived microvesicles. Adult controls (n = 6) analyzed for RBC/CD235a-derived microvesicles. NA: not analyzed.

Significantly higher levels of circulating microvesicles (derived from platelets and leukocytes), and microvesicles containing Stx2 (derived from platelets, leukocytes and RBCs), were detected in plasma during the acute phase of HUS compared to after recovery ([Table 1](#ppat.1004619.t001){ref-type="table"}). Levels of platelet and leukocyte microvesicles at recovery were similar to those found in controls.

Microvesicles levels were slightly elevated in patients with hemorrhagic colitis (n = 5, Patients 15--19) and two of these patients exhibited Stx2 in microvesicles from platelets and leukocytes. No Stx2 was detected in microvesicles from the controls (n = 10) or patients with acute renal failure (n = 2), as expected. In the absence of membrane permeabilization with saponin no Stx2 was detected on the surface of microvesicles.

Blood-cell derived microvesicles were demonstrated in the kidney of a patient with HUS {#sec004}
--------------------------------------------------------------------------------------

A renal cortical biopsy from a patient with *E. coli* O157:H7-induced HUS (Patient 14) was examined by immune-electron microscopy labeled for Stx2. Thirty cellular profiles were examined in glomerular and tubular regions. Numerous platelet- and leukocyte-derived microvesicles labeled for Stx2 were demonstrated adjacent to and within endothelial cells ([Fig. 1A,B](#ppat.1004619.g001){ref-type="fig"}). Altogether, 0--10 platelet- or leukocyte-derived microvesicles containing Stx2 were demonstrated per cellular profile. No specific binding of control antibodies was observed in the tissue in general, and specifically on or within microvesicles.

![Stx2-containing blood cell-derived microvesicles detected in the renal cortex of a HUS patient.\
(**A**) Ultramorphology showing an overview from the renal cortex of a patient with HUS (patient 14) including a glomerular capillary with two boxes magnified in (B). Scale bar: 2 μm. P: podocyte, GEC: glomerular endothelial cell, GBM: glomerular basement membrane, L: leukocyte. (**B**) Renal cortex of a the same HUS patient labeled with anti-Stx2 (5 nm, arrowhead), anti-CD42b (10 nm, arrow) to detect platelet-derived microvesicles or anti-CD45 (10 nm, arrow) to detect leukocyte-derived microvesicles. Microvesicles were defined by their size (shed microvesicles: ≤ 1μm, apoptotic bodies: 1--5 μm) and their cellular origin based on the presence of platelet- or leukocyte-markers. Stx2-containing microvesicles were detected in glomerular- and peritubular capillary endothelium. The two upper panels are magnifications of the two boxes depicted in (A). Scale bar: 100 nm.](ppat.1004619.g001){#ppat.1004619.g001}

Stx2 is present in circulating microvesicles from EHEC-infected and Stx2-treated mice {#sec005}
-------------------------------------------------------------------------------------

The findings in HUS patients were further studied in EHEC-inoculated mice. BALB/c mice (n = 10) were infected with the Stx2-producing *E. coli* O157:H7 strain 86--24. Blood was drawn from two mice each day between days 2--6 after inoculation, before any symptoms developed, and plasma levels of circulating microvesicles were measured by flow cytometry and compared to control mice (n = 2, samples taken on day 6). Plasma taken between days 2--5 showed considerably higher levels of circulating platelet- and leukocyte-derived microvesicles ([Fig. 2](#ppat.1004619.g002){ref-type="fig"}) compared to the controls. Stx2 was detected in microvesicles released from platelets ([Fig. 2A](#ppat.1004619.g002){ref-type="fig"}), neutrophils ([Fig. 2B](#ppat.1004619.g002){ref-type="fig"}) and monocytes ([Fig. 2C](#ppat.1004619.g002){ref-type="fig"}) at all time points (not assayed for RBCs). No Stx2 was detected in microvesicles from control mice.

![Stx2-containing blood cell-derived microvesicles were detected in the circulation of mice infected with *E. coli* O157:H7.\
Microvesicles were isolated from whole blood of BALB/c mice (n = 10) inoculated with the Stx2-producing *E. coli* O157:H7 strain and analyzed by flow cytometry. Samples were taken between days 2 and 6 after infection. Microvesicles were labeled with anti-Stx2 and anti-mouse CD41:APC (**A**) to identify platelet-derived microvesicles, anti-mouse Ly-6G:PE (**B**) to identify neutrophil-derived microvesicles or a combination of anti-mouse CD45R/B222:PerCp-Cy5.5 and anti-mouse Ly-6G:PE (**C**) to identify monocyte-derived microvesicles. All microvesicles were labeled with cell-specific and Stx2 antibodies. Stx2-containing microvesicles were mostly detected on days 2--5 after infection. No labeling of the Stx2 antibody was detected in the non-infected mice (n = 2, day 6). (**D**) Platelet-derived microvesicles (labeled with anti-mouse CD41:APC) and stained for Stx2 were isolated from mice inoculated with Stx2-producing *E. coli* O157:H7 strain 86--24 and the isogenic non-Stx producing *E. coli* O157:H7 strain 87--23 on day 3 post-inoculation. Only mice inoculated with strain 86--24 exhibited Stx within microvesicles. \* Denotes *P*\<0.05. (**E**) Platelet-derived microvesicles labelled for Stx2 were isolated from mice injected with Stx2 i.p. or PBS controls. An increase in microvesicles was noted in Stx-treated mice 3--4 days after treatment.](ppat.1004619.g002){#ppat.1004619.g002}

In a separate experiment mice were inoculated with the Stx2-producing *E. coli* O157:H7 strain 86--24 (n = 5) and the isogenic non-Stx producing *E. coli* O157:H7 strain 87--23 (n = 4) and sacrificed 3 days after inoculation. There was no statistical difference between the strains regarding the total number of platelet-derived microvesicles but only microvesicles from mice infected with the Stx2-producing strain contained Stx, as expected ([Fig. 2D](#ppat.1004619.g002){ref-type="fig"}). Similarly, mice injected intraperitoneally with Stx2 (n = 9) also exhibited an increase in Stx2 within platelet-derived microvesicles on days 2--4 post-injection ([Fig. 2E](#ppat.1004619.g002){ref-type="fig"}), albeit at lower concentrations than in EHEC-infected mice.

In vivo transfer of Stx2 to kidney cells within blood cell-derived microvesicles {#sec006}
--------------------------------------------------------------------------------

Electron microscopy of kidneys from mice infected with *E. coli* O157:H7 showed extensive glomerular endothelial ([Fig. 3A](#ppat.1004619.g003){ref-type="fig"}) and tubular epithelial ([Fig. 3B](#ppat.1004619.g003){ref-type="fig"}) damage on Day 6 post-inoculation, in comparison to controls ([Fig. 3C,D](#ppat.1004619.g003){ref-type="fig"}). Kidneys from infected and control mice were examined for the presence of Stx2-containing platelet- and leukocyte-derived microvesicles (≤1 μm) on days 2--6 after inoculation. On days 3--6 post-inoculation Stx2-containing platelet- and leukocyte-derived microvesicles were observed on ([Fig. 3E-H](#ppat.1004619.g003){ref-type="fig"}) and within ([Fig. 3I](#ppat.1004619.g003){ref-type="fig"}) glomerular endothelial cells as well as within endothelial cells in peritubular capillaries ([Fig. 3J](#ppat.1004619.g003){ref-type="fig"}). Furthermore, Stx2 containing blood cell-derived microvesicles were identified within the glomerular ([Fig. 3K](#ppat.1004619.g003){ref-type="fig"}) and tubular basement membranes ([Fig. 3L](#ppat.1004619.g003){ref-type="fig"}) and within podocytes ([Fig. 3K](#ppat.1004619.g003){ref-type="fig"}) and tubular epithelial cells ([Fig. 3M,N](#ppat.1004619.g003){ref-type="fig"}). At all localizations Stx2 was identified within microvesicles as well as in free form ([Fig. 3N](#ppat.1004619.g003){ref-type="fig"}). Quantification of Stx2 containing platelet- and leukocyte-derived microvesicles was carried out in 50 cell profiles in the glomerular and peritubular capillary endothelium as well as in the tubular epithelium in infected and control mice as presented in [Table 2](#ppat.1004619.t002){ref-type="table"}. The results indicate that most Stx2-containing microvesicles were of platelet origin and localized to the glomerular and peritubular capillary endothelium in the infected mice. In the non-infected mice minimal background signal was observed (0--3 gold particles). Control antibodies bound minimally and unspecifically.

![Ultramorphology of the renal cortex in mice infected with *E. coli* O157:H7.\
Representative overviews of glomerular (**A**, box depicts an area of endothelial damage with detachment from the basement membrane, arrow indicates thickening of the glomerular basement membrane and arrowheads point to fragmented RBCs in a glomerular capillary) and tubular (**B**) damage in infected mice. These are compared to a glomerulus (**C**, showing thin basement membranes and normal round RBC in a glomerular capillary) and tubulus (**D**) from uninfected mice, all taken on day 6 post-inoculation. Samples were co-incubated with rabbit anti-Stx2 (5 nm, arrowhead) and rat anti-mouse CD41 (10 nm, detects platelet-derived microvesicles, arrow) or rat anti-mouse CD45 (10 nm, detects leukocyte-derived microvesicles, arrow) showing binding of Stx2-containing microvesicles to glomerular (**E**, showing platelet microvesicle, **F**, showing leukocyte microvesicle) and peritubular capillary endothelial cells (**G**, platelet microvesicle, **H**, leukocyte microvesicle). Stx2-containing microvesicles were detected within glomerular (**I**, platelet microvesicle, see inset for enlargement) and peritubular (**J**, leukocyte microvesicle) capillary endothelial cells, glomerular (**K**) and tubular (**L**) basement membranes (both showing platelet microvesicles), within podocytes (**K**) and tubular epithelial cells (**M**, leukocyte microvesicle, **N**, platelet microvesicle). E-N taken on day 4 post-inoculation. Scale bar 100 nm. For detailed enlargement of microvesicles in panels I-N see [S2 Fig.](#ppat.1004619.s004){ref-type="supplementary-material"} (in supporting information). P: podocyte, RBC: red blood cell, TE: tubular epithelial cell, BB: brush border, TBM: tubular basement membrane, M: mesangial cell, GEC: glomerular endothelial cell, GBM: glomerular basement membrane, PCE: peritubular capillary endothelium.](ppat.1004619.g003){#ppat.1004619.g003}

10.1371/journal.ppat.1004619.t002

###### Numbers and cellular origin of Stx-positive microvesicles in mice infected with *E. coli* O157:H7.

![](ppat.1004619.t002){#ppat.1004619.t002g}

                                                           Glomerular endothelium   Peritubular capillary endothelium   Tubular epithelium                               
  -------------------------------------------------------- ------------------------ ----------------------------------- -------------------- ------------- ------------- ------------
  2                                                        33 (18--44)              21 (10--25)                         21 (18--24)          13 (11--15)   9 (7--14)     7 (5--10)
  3                                                        49 (29--60)              23 (15--32)                         43 (39--52)          20 (17--22)   11 (6--14)    8 (6--14)
  4                                                        53 (41--66)              22 (14--30)                         46 (40--56)          22 (16--28)   13 (10--19)   10 (7--18)
  5                                                        57 (38--75)              24 (14--31)                         48 (38--55)          22 (16--29)   13 (8--25)    9 (7--19)
  6                                                        55 (34--65)              25 (19--31)                         47 (39--62)          24 (19--31)   12 (9--20)    10 (8--20)
  6 (non-infected)[^a^](#t002fn002){ref-type="table-fn"}   1 (1--2)                 2 (1--3)                            1 (0--2)             1 (1--2)      0             0

Data are expressed as median and (range) of microvesicles positive for each specific surface marker and Stx2. Values are derived from 50 cellular profiles from two independent experiments.

^a^, These uninfected mice were sacrificed on Day 6, the infected mice were sacrificed on Days 2--6.

Stx2 induced release of blood cell-derived microvesicles containing Stx2 in vitro {#sec007}
---------------------------------------------------------------------------------

Microvesicles containing Stx2 were detected in whole blood stimulated with Stx2 by flow cytometry. Stx2 induced a significant increase in the release of microvesicles compared with the phosphate-buffered saline (PBS)-treated samples ([Fig. 4A](#ppat.1004619.g004){ref-type="fig"}). Stx2 was detected in microvesicles released from platelets, monocytes and neutrophils. Most microvesicles were of platelet origin. Similarly, purified RBCs stimulated with Stx2 released microvesicles in which Stx2 was detected. No Stx2 was detected within microvesicles from the PBS-treated samples, or on the surface of microvesicles.

![Blood cell-derived microvesicles transfer Stx2 to glomerular endothelial cells in vitro.\
(**A**) Data are expressed as median and (range) of microvesicles positive for each membrane specific marker/mL of plasma. ^a^, Microvesicles released from whole blood (n = 6). ^b^, Microvesicles released from purified RBCs (n = 10). \*\*\* Denotes *P* value \<0.001, \*\* *P*\<0.01 and \* *P*\<0.05 when comparing microvesicle generation in whole blood stimulated with Stx2 with unstimulated whole blood, or RBCs stimulated with Stx2 with unstimulated RBCs. ND: not detected. (**B---H**) Conditionally immortalized glomerular endothelial cells (CiGEnC) were incubated with microvesicles isolated from Stx2-stimulated whole blood for 1--24 h. Cells were stained with rabbit anti-Stx2 (5 nm gold particles) and mouse anti-human CD42b or mouse anti-human CD45 to identify platelet- or leukocyte-derived microvesicles, respectively (10 nm gold particles). After 1 h of incubation Stx2-containing platelet- (**B**, **C**) and leukocyte- (**D**) derived microvesicles bound to and appeared to fuse with the cell membrane or were found in the cell cytoplasm (**E**, platelet microvesicle). At 3 h Stx2-containing microvesicles are demonstrated within early endosomes, see arrows (**F**, leukocyte microvesicle, anti-early endosome antibody detected with 20 nm gold particles). Endosome membranes were disrupted after 12 h, see arrow (**G**, leukocyte microvesicle) and Stx2 was bound to ribosomes (arrowheads) in the cytoplasm after 24 h (**H**, anti-ribosome antibody detected with 20 nm gold particles).](ppat.1004619.g004){#ppat.1004619.g004}

Blood cell-derived microvesicles transferred Stx2 to glomerular endothelial cells in vitro {#sec008}
------------------------------------------------------------------------------------------

Transfer of Stx2 to glomerular endothelial cells by blood cell-derived microvesicles was investigated by incubation of conditionally immortalized glomerular endothelial cells (CiGEnC) with Stx2-containing microvesicles and visualization by electron microscopy (n = 2). Results showed that platelet- and leukocyte-derived Stx2-containing microvesicles bound to ([Fig. 4B,C](#ppat.1004619.g004){ref-type="fig"}) and fused with CiGEnC after 1h ([Fig. 4D](#ppat.1004619.g004){ref-type="fig"}) and were demonstrated within the cell cytoplasm ([Fig. 4E](#ppat.1004619.g004){ref-type="fig"}) or in early endosomes ([Fig. 4F](#ppat.1004619.g004){ref-type="fig"}) after 3h. At 12h the membranes of the early endosomes were disrupted and free Stx2 was visualized in the cytoplasm ([Fig. 4G](#ppat.1004619.g004){ref-type="fig"}). After 24h Stx2 was bound to ribosomes in the cytoplasm ([Fig. 4H](#ppat.1004619.g004){ref-type="fig"}). No specific binding of the control antibodies was detected.

Stx2 transferred within blood cell-derived microvesicles affected cell viability {#sec009}
--------------------------------------------------------------------------------

The cytotoxic effect of Stx2-containing microvesicles was examined by incubation of CiGEnC with microvesicles isolated from Stx2-treated whole blood. These microvesicles induced significantly more cell death compared to microvesicles from untreated blood (*P*\<0.001, [Fig. 5A](#ppat.1004619.g005){ref-type="fig"}). After 36h incubation the number of viable cells was reduced to a median of 30% (range 24--53%, n = 5) in the samples incubated with microvesicles from the Stx2-treated blood samples whereas a median of 75% (range 63--87%) of the cells treated with microvesicles from the unstimulated blood samples were viable in comparison to the untreated cells (defined as 100% viability). Cells treated with microvesicles containing the enzymatically inactive Stx2 mutant showed a slight reduction in viability (median 85%, range 80--88%). CiGEnC incubated with Stx2-treated washed samples (purified Stx2 exposed to washing steps similar to microvesicles before exposure to the cells, but without microvesicles) exhibited 62% (range 57--73%) viability while treatment of the cells with pure Stx2 (without washing steps) reduced viability to 46% (range 40--51%) ([Fig. 5A](#ppat.1004619.g005){ref-type="fig"}).

![Microvesicles containing Stx2 affected the viability and inhibited protein synthesis in CiGEnC.\
The effect of Stx2-containing microvesicles on cell viability was examined by use of a crystal violet assay (**A**). Data are expressed as percentage of control cell viability defined as 100%. Representative data from five experiments are depicted as the median of triplicate wells. \*\*\* Denotes *P* value \<0.001 and \* *P*\<0.05. (**B**) Protein synthesis was measured as the incorporation of \[^35^S\]-methionine into total protein. Data are expressed as percent and 100% represents the untreated cells incubated under the same conditions but without microvesicles. All experiments were done in duplicate and the experiment was repeated three times. MVs untreated sample: whole blood was exposed to PBS for 1 hr, microvesicles (MVs) were isolated and incubated with CiGEnC for 36 hr; MVs Stx2-treated sample: isolated from whole blood treated with Stx2 (200 ng/mL diluted in PBS) for 36h; MVs Stx2 mutant-treated sample: isolated from whole blood treated with Stx2 mutated in the catalytic A subunit for 36h: Stx2-treated sample: purified Stx2 was exposed to washing steps similar to microvesicles before exposure to the cells; Stx2: cells were exposed to pure Stx2 (200 ng/mL) without washing steps.](ppat.1004619.g005){#ppat.1004619.g005}

Stx2 transferred within blood cell-derived microvesicles inhibited protein synthesis {#sec010}
------------------------------------------------------------------------------------

To determine if the cytotoxic effect of microvesicles containing Stx2 was associated with inhibited protein synthesis cultured CiGEnC were incubated with Stx2-containing microvesicles and \[^35^S\]-methionine incorporation was measured. Protein synthesis was reduced to 9% (median, range 8--32%, n = 3, [Fig. 5B](#ppat.1004619.g005){ref-type="fig"}) in CiGEnC treated with Stx2-containing microvesicles compared to untreated cells. Incubation of cells with Stx2-containing media exposed to washing steps similar to the microvesicles reduced protein synthesis to 44--47% (n = 3, median 45%), respectively, and exposure of cells to purified Stx2 inhibited protein synthesis to 6--15%, (n = 3, median 10%). Cells treated with microvesicles from unstimulated samples showed a slightly increased protein synthesis (median 110%, range 93--124%, n = 3).

Discussion {#sec011}
==========

In this study we showed that Stx2, after binding to blood cells, was released from these cells within microvesicles and that these microvesicles could thereafter bind to renal glomerular and peritubular capillary endothelial cells and undergo endocytosis. Inside renal cells Stx was released from microvesicles and exerted a cytotoxic effect equivalent to purified toxin. Not all toxin was released from microvesicles, as certain Stx2-containing microvesicles were transferred from cell to cell, even via the glomerular or tubular basement membranes, thus reaching podocytes and tubular epithelial cells. This mechanism of Stx endocytosis would be independent of the toxin Gb3 receptor. The transfer of virulence factors within host blood cell-derived microvesicles is a novel mechanism of bacterial pathogenesis.

Several mechanisms of microvesicle-mediated communication with cells have been described. Microvesicles can bind to cells by expressing specific receptors, by fusion with the cell membrane, by endocytosis and by release of mediators that bind to the cells \[[@ppat.1004619.ref036]\]. Ultramorphological results presented here indicate that Stx2-containing microvesicles underwent endocytosis as they were labeled with blood cell markers within glomerular and peritubular capillary endothelial cells. In vitro experiments using glomerular endothelial cells indicated that microvesicles were either taken up by early endosomes or underwent fusion with the cell membrane. Blood cell-derived microvesicles taken up in endosomes were not destroyed within endothelial cells and could thus transit intact between cells and through basement membranes until the contents of the microvesicle were released intracellularly.

The necessity of the Gb3 or another glycolipid receptor for Stx internalization and the induction of cellular injury has been described \[[@ppat.1004619.ref037]\], and in mice Gb3-deficiency conferred resistance to the effects of Stx administered intravenously \[[@ppat.1004619.ref038]\]. However, it is, as yet, unclear whether Stx binds to and damages human intestinal epithelial cells or gains access to the systemic circulation by other pathways. The toxin is capable of damaging human intestinal cells that lack the receptor \[[@ppat.1004619.ref039]\] and Stx was found within non-Gb3 expressing intestinal cells of a patient infected with EHEC \[[@ppat.1004619.ref040]\]. Furthermore, Stx B subunit was shown to undergo endocytosis by macropinocytosis in a clathrin-independent manner \[[@ppat.1004619.ref040]\]. Another Gb3-independent mechanism of toxin binding was exhibited on neutrophils (lacking the Gb3 and Gb4 receptor) which bound Stx via its A enzymatic subunit \[[@ppat.1004619.ref041],[@ppat.1004619.ref042]\]. Here we demonstrated an alternative Gb3-independent process of toxin uptake mediated by the endocytosis of toxin-containing microvesicles derived from blood cells. The latter process requires the presence of Gb3 in order for the initial binding of Shiga toxin to platelets \[[@ppat.1004619.ref043]\], monocytes \[[@ppat.1004619.ref044]\] and red blood cells \[[@ppat.1004619.ref045]\] to occur.

After inducing hemorrhagic colitis \[[@ppat.1004619.ref046]\] Stx will come in contact with blood cells. The toxin will thus bind to blood cells, including platelets \[[@ppat.1004619.ref026],[@ppat.1004619.ref047]\], leukocytes \[[@ppat.1004619.ref023],[@ppat.1004619.ref044],[@ppat.1004619.ref048]--[@ppat.1004619.ref050]\] and possibly RBCs, leading to blood cell activation and membrane blebbing \[[@ppat.1004619.ref022]\]. Shiga toxin may be internalized within platelets \[[@ppat.1004619.ref026]\], macrophages \[[@ppat.1004619.ref051]\] and possibly within other blood cells. The internalized toxin could thus be released within microvesicles. An alternative speculative explanation for the presence of Shiga toxin within microvesicles is the loss of lipid asymmetry in the membrane lipid bilayer typical for microvesicles by which substances bound to lipid receptors on the outer Gb3 or an alternative toxin receptor of a microvesicle may potentially flip to the inside while remaining membrane-bound \[[@ppat.1004619.ref052]\]. Free toxin is minimal in the bloodstream of infected patients \[[@ppat.1004619.ref021],[@ppat.1004619.ref053],[@ppat.1004619.ref054]\] and thus most of the toxin is cell-bound or internalized. We propose, based on the results presented here, that the release of toxin-containing microvesicles from these blood cells will enable the transfer of toxin to its target cells. This seems more likely than the transfer of toxin from one cell to another after binding to its receptor and endocytosis. Toxin within microvesicles will, in this manner, evade host immune recognition and then be taken up by renal cells and induce cell damage.

An interesting finding was that Stx-containing microvesicles were present in both glomerular and peritubular capillary endothelial cells simultaneously. This would indicate that circulating microvesicles affect both cell types thus explaining why intense damage to both glomeruli and tubuli occurs during Stx-mediated HUS \[[@ppat.1004619.ref003],[@ppat.1004619.ref055]\]. This degree of damage to both cell types was also noted in the murine model of infection where glomerular endothelial cell damage would be achieved in a Gb3-independent manner as murine glomerular endothelial cells do not express Gb3 \[[@ppat.1004619.ref007]\]. Similar glomerular findings were noted in murine models of Stx injection \[[@ppat.1004619.ref018]--[@ppat.1004619.ref020]\], which could also be explained by an indirect effect of toxin on tubular epithelial cells (which express Gb3 \[[@ppat.1004619.ref007]\]) extending to ischemic damage of the entire nephron. However, our results show that toxin within microvesicles is internalized in non-Gb3 expressing cells and we therefore suggest that the toxin affects cells that do not express the specific glycolipid receptor by this mechanism.

Toxin-containing microvesicles did not appear to be targeted for lysosomal degradation and could thus proceed to affect cell viability after release of contents. Once within a cell free StxA1 will be translocated in a retrograde fashion to the large ribosomal subunit where it inhibits protein synthesis and ultimately leads to cell death \[[@ppat.1004619.ref012]\]. A certain amount of toxin was demonstrated in free form within the cell cytoplasm, enabling cellular damage to occur, while other toxin-containing microvesicles passed through cells without total release of contents. It is thus unclear if microvesicles undergo partial release of their contents while passing within a cell or if total release of microvesicle contents occurs and which mechanisms regulate the process of microvesicle uptake, release of contents and/or transfer to a neighboring cell.

An interesting finding was that mice injected with Stx2 also exhibited the presence of platelet-derived microvesicles containing Stx, although at lower concentrations than mice inoculated with EHEC. EHEC infection will have a more profound effect in mice, as persistent colonization will allow continuous release of toxin, as well as other bacterial virulence factors, followed by a more severe host response \[[@ppat.1004619.ref005],[@ppat.1004619.ref008],[@ppat.1004619.ref009]\]. This would explain why EHEC infection promotes the release of higher numbers of toxin-containing microvesicles. Nevertheless, the murine model using purified toxin and in vitro experiments demonstrate that toxin may bind to blood cells and be released within microvesicles even in the absence of other bacterial or host systemic as well as intestinal factors involved in EHEC infection.

Microvesicles have been well-characterized with regard to their ability to induce thrombosis by expressing phosphatidylserine capable of activating coagulation factors \[[@ppat.1004619.ref056]\] and by expression of tissue factor \[[@ppat.1004619.ref022],[@ppat.1004619.ref057],[@ppat.1004619.ref058]\]. In Stx-mediated HUS they also possess complement deposits indicating that complement activation occurred on the parent cells and reflecting the inflammatory and thrombogenic process occurring during HUS \[[@ppat.1004619.ref027]\]. Here we defined a new mechanism of virulence in this non-invasive bacterial infection showing that microvesicles transfer bacterial toxin to target cells. Thus blood cell derived-microvesicles may play an important role in the development of HUS. Future studies will address the therapeutic option of interference with microvesicle release during EHEC infection. In addition to the damaging effects of microvesicles presented here, microvesicle release may also be a beneficial mechanism by which cells rid themselves of unwanted substances (foreign as well as host-derived). The effects of blocking microvesicle release, particularly from blood cells, will require further study.

Materials and Methods {#sec012}
=====================

Subjects {#sec013}
--------

Blood samples were available from 9 boys and 7 girls, aged 1--10 years (median 4 years, patients 1--12 and 15--18 in [S1 Table](#ppat.1004619.s001){ref-type="supplementary-material"}, supporting information), treated for EHEC infection at the Department of Pediatrics, Skåne University Hospital, Lund and Malmö. Samples were obtained within three days of admission while all children still had diarrhea and all but four had HUS. Blood samples were also available from two adults with EHEC infection, one with and one without HUS, treated at the Department of Infectious Diseases, Skåne University Hospital (Patients 13 and 19). HUS was defined as hemolytic anemia (hemoglobin levels \<100 g/L), thrombocytopenia (platelet counts \<140 x 10^9^/L) and acute renal failure. Patients 7--12 were previously described \[[@ppat.1004619.ref027],[@ppat.1004619.ref059]\].

Samples were also available from four pediatric controls, three girls and one boy aged 6--15 years (median 9 years), seen at the outpatient clinic for unrelated conditions and from two patients with acute renal failure. These patients were treated for acute myeloid leukemia (a 13-year-old boy) or for acute renal failure associated with sepsis (an adult male at the Department of Nephrology). Blood was, in addition, obtained from 15 healthy adult volunteers (9 women, 6 men) not using any medications.

A renal cortical biopsy was available from a 13-year-old boy with EHEC-associated HUS (Patient 14). The biopsy was previously described \[[@ppat.1004619.ref059]\] and performed 2 days after the development of HUS. Tissue was prepared for paraffin-embedding according to hospital routines and used in electron microscopy.

Blood collection and isolation of platelet-free-plasma {#sec014}
------------------------------------------------------

Blood was drawn by venipuncture into vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ) containing 0.5 mL of 0.129 M sodium citrate (Becton Dickinson) through an intravenous cannula or a butterfly needle (Terumo Medical products Hangzhou CO, Hangzhou, China) with low tourniquet. The first tube following venipuncture was discarded. Within 60 minutes of blood collection, blood cells were removed by centrifugation (2600×g, 15 min, 20°C) followed by a second centrifugation step (9900×g, 5 min, 20°C) to obtain platelet-free-plasma (PFP). PFP was carefully removed without disturbing the buffy coat, divided in 200 μL aliquots and stored at---80°C until analyzed for the presence of microvesicles.

Mice {#sec015}
----

BALB/c mice were bred in the animal facilities of the Department of Microbiology, Immunology and Glycobiology, Lund University. Both female and male mice were used at 9--14 weeks of age. Studies from our group and others have shown that BALB/c mice develop symptoms after EHEC infection \[[@ppat.1004619.ref060],[@ppat.1004619.ref061]\] and Stx injection \[[@ppat.1004619.ref062]\].

Bacteria {#sec016}
--------

The Stx2-producing *E. coli* O157:H7 strain 86--24 and the isogenic non-Stx producing *E. coli* O157:H7 strain 87--23 (kindly provided by A. D. O\'Brien, Uniformed Services University of the Health Sciences, Bethseda, MD) were previously characterized \[[@ppat.1004619.ref009]\]. Streptomycin-resistant derivatives of these strains were isolated as previously described \[[@ppat.1004619.ref008]\]. Bacteria were grown overnight at 37°C in Luria-Bertani broth supplemented with 50 μg/mL Streptomycin sulfate (Sigma-Aldrich, St. Louis, MO), harvested by centrifugation, washed in sterile phosphate buffered saline (PBS, pH 7.4, Medicago AB, Uppsala, Sweden) and re-suspended in 20% (w/v) sucrose and 10% (w/v) NaHCO~3~ in sterile water at a concentration of 10^9^ colony forming units (CFU)/mL. The bacterial concentration was confirmed by plating serial dilutions of the bacterial suspension on Luria-Bertani agar plates. Each mouse was infected orally with 10^8^ CFU in 100 μl solution.

Infection protocol {#sec017}
------------------

The *E. coli* O157:H7 infection protocol has been previously described \[[@ppat.1004619.ref006]\]. Fecal samples were collected on day one, three and five after inoculation to confirm colonization. In this infection model symptoms usually develop on day 7--8 after inoculation. Mice were anesthetized with isoflurane (Forene, Abbott, Wiesbaden, Germany), blood was collected from vena saphena and by heart puncture, and the mice were then sacrificed by cervical dislocation at day 2, 3, 4, 5 or 6 after inoculation. For analysis of microvesicles and blood urea nitrogen (BUN, QuantiChrom urea assay kit, Bioassay Systems, Hayward, CA), blood was collected into citrated syringes and treated with sterile-filtered paraformaldehyde (PFA, Histolab, Gothenburg, Sweden) at a final concentration of 2% to enable transfer of the sample. For analysis of platelet counts blood was collected in microvettes with EDTA (Sarstedt, Nümbrecht, Germany) and fixed in 0.5% PFA. Platelet counts were assayed using a Sysmex Kx-21N system according to the manufacturer's instructions (Sysmex America, Mundelein, IL). Platelet counts and BUN are presented in [S1 Fig.](#ppat.1004619.s003){ref-type="supplementary-material"} Kidneys were fixed overnight in 2.5% glutaraldehyde in 0.15 M sodium-cacodylate buffer (pH 7.9).

Intraperitoneal injection of Stx2 {#sec018}
---------------------------------

Purified Stx2 (obtained from C Thorpe, Phoenix Lab, Tufts Medical Center, Boston, MA) was diluted in PBS and injected intraperitoneally at a dose 285 pg/g weight as previously described \[[@ppat.1004619.ref008]\]. In this model symptoms usually develop on day 3--5 after injection. At day 1, 2, 3 or 4 blood was collected from vena saphena and by heart puncture after isoflurane anesthesia and the animals were then sacrificed by cervical dislocation. Blood samples for analysis of microvesicles were treated as described above.

Isolation, detection and identification of murine microvesicles {#sec019}
---------------------------------------------------------------

Murine microvesicles was purified from whole blood fixed in 2% PFA by centrifugation for 15 min at 1500g at 20°C to remove the pellet of blood cells. The platelet-poor-plasma supernatant was collected and further centrifuged at 13000g for 3 min to obtain platelet-free-plasma in the supernatant. The sample was diluted in sterile-filtered PBS and further centrifuged for 45 min at 24000g at 15°C to obtain a precipitate containing a microvesicle-enriched suspension.

Identification of blood cell-derived microvesicles in murine plasma was carried out as per [S2 Table](#ppat.1004619.s002){ref-type="supplementary-material"} (in supporting information). Using flow cytometry microvesicles were identified by incubation of the enriched suspension with a mixture of rat anti-mouse CD41:APC (1:40, detects platelets), rat anti-mouse CD45R/B220:PerCP-Cy5.5 (1:300, detects monocytes, B-cells, NK-cells and T-cells) and rat anti-mouse Ly-6G:PE (1:300, detects granulocytes and monocytes) or isotype controls IgG~1~:APC, IgG~2a~:PE or IgG~2a~:PerCP-Cy5.5 (all from BD Biosciences, San Diego, CA) for 20 min at rt. Events staining positively for both CD45R/B220 and Ly-6G were considered to represent microvesicles released from monocytes while events staining for Ly-6G alone were considered to represent microvesicles released from neutrophils.

Stx2 was detected by incubation with polyclonal rabbit anti-Shiga toxin (Stx)2 B-subunit (1:200, BEI Resources, Manassas, VA, diluted in 0.1% saponin (Sigma-Aldrich) to enable intravesicular staining of Stx2). Rabbit IgG (eBioscience, San Diego, CA) was used as the negative control and swine anti-rabbit:FITC F(ab´)~2~ (1:300, Dako, Glostrup, Denmark) as the secondary antibody.

Transmission electron microscopy of human and murine kidneys {#sec020}
------------------------------------------------------------

Renal tissue sections from the HUS patient were embedded and subject to antigen retrieval with metaperiodate\[[@ppat.1004619.ref063]\]. Grids were blocked with 5% (v/v) goat serum diluted in 0.2% bovine serum albumin (pH 7.6, Aurion, Wageningen, Netherlands) for 15 min followed by incubation with polyclonal rabbit anti-Stx2 B-subunit (1:80) and mouse anti-human CD42b (1:80, to detect platelets) or mouse anti-human CD45 (1:100, to detect leukocytes, both from BioLegend, San Diego, CA) overnight at 4°C. Samples were then incubated with gold-conjugated goat anti-rabbit IgG:5nm (1:10) or goat anti-mouse IgG:10nm (1:20, both from BBI, Cardiff, UK) for 1h at rt followed by fixation in 2% glutaraldehyde and post-stained with uranyl acetate and lead citrate. Rabbit IgG or mouse IgG (BioLegend) were used as negative controls.

Similarly, renal tissues from mice were fixed and sectioned as described above and incubated with rabbit anti-Stx2 (1:80), rat anti-mouse CD41 (1:100, detects platelets) or rat anti-mouse CD18 (1:100, detects leukocytes, both from eBioscience) and gold-conjugated reagents as described above. Rabbit IgG, rat IgG~1~ or rat IgG~2b~ (all from eBioscience) was used as negative controls.

Sections were examined with a transmission electron microscope (CM100 Twin, Philips, Eindhoven, Holland) operated at a 60 kV accelerating voltage. The images were recorded with a side-mounted Olympus Veleta camera (Olympus, Münster, Germany).

Stimulation of human whole blood or purified red blood cells with Stx2 {#sec021}
----------------------------------------------------------------------

Whole blood diluted 1:2 in LPS-free DMEM (Invitrogen, Paisley, UK) containing Gly-Pro-Arg-Asp (GPRP, 10 μM, Sigma-Aldrich) was incubated with purified Stx2 (200 ng/mL, a gift from T.G. Obrig, Department of Microbiology and Immunology, University of Maryland, Baltimore or obtained from C. Thorpe as above) or the catalytically inactive Stx2-mutant (mutated in the enzymatic A subunit active site \[[@ppat.1004619.ref064]\] 200 ng/mL, from C. Thorpe) for 1h. The LPS content of the Stx2 preparation (from T.G. Obrig) was assayed by the limulus amebocyte assay (Coatex, Gothenburg Sweden) and found to be less than 50 pg/ml (the detection limit) and the preparations from C Thorpe were assayed by Endochrome 140 (Charles River, L'Arbresle Cedex, France) and found to be 25 ng/mL (300 endotoxin units/mL). For electron microscopy experiments whole blood was first incubated with Stx2 for 1h followed by incubation with a calcium ionophore (A23187, 10 μM, Sigma-Aldrich) for 30 min to increase the total numbers of microvesicles.

Red blood cells (RBCs) were isolated immediately after blood collection by centrifugation (830g, 5 min, 20°C), and washed three times in PBS. The RBCs (4.5x10^8^/mL) were diluted 1:2 in RBC-donor specific citrated plasma and LPS-free RPMI1640 (Invitrogen) and incubated with Stx2 for 40 min at 37°C under gentle shaking. All samples were analyzed for the release of microvesicles containing Stx2 by flow cytometry, as described below.

Isolation of human microvesicles {#sec022}
--------------------------------

Microvesicles were isolated from patient or control platelet-free-plasma or from in vitro stimulation experiments (whole blood and RBC stimulation) as previously described \[[@ppat.1004619.ref027]\] with the following modifications. Aliquots of platelet-free-plasma (200 μL) were thawed in a 37°C water bath for 5 min and centrifuged at 20800g for 10 min at 7°C. 150 μL of the supernatant were discarded and the remaining 50 μL were washed twice (for flow cytometry) or five times (for the cytotoxicity assay and electron microscopy) in sterile Hank's Balanced Salt Solution without Ca^2+^ and Mg^2+^ (HBSS, PAA Laboratories GMBH, Pasching, Austria) and centrifuged as above. For flow cytometry assay microvesicles were fixed in 1% PFA for 30 min. To reduce background all buffers, cell media and PFA were filtered through a 0.2 μm pore-sized filter (Pall Corporation, Ann Arbor, MI).

Labeling of microvesicles with cell-specific antibodies {#sec023}
-------------------------------------------------------

Subpopulations of blood cell-derived microvesicles were determined by incubation with mouse anti-human CD42b:APC (1:20), mouse anti-human CD38:PerCP-Cy5.5 (1:100, detects monocytes), mouse anti-human CD66:PE (1:40, neutrophils) or mouse anti-human CD235a:PE (1:800, RBCs) for 30 min in the dark. Mouse IgG~1~:APC, mouse IgG~1~:PerCP-Cy5.5, mouse IgG~1~:PE or mouse IgG~2b~:PE were used as iso-type controls (all from BD Biosciences).

Detection of Stx2 in microvesicles by flow cytometry {#sec024}
----------------------------------------------------

Microvesicles from patients or in vitro experiments were fixed in 1% PFA and incubated with polyclonal rabbit anti-Stx2 B-subunit (1:200, used in whole blood experiments) or monoclonal mouse anti-Stx2 IgG~1~ (11E10, 200 ng/mL, a gift from T.G. Obrig, used in RBC experiments) for 30 min. The choice of anti-Stx used depended on the species origin of the microvesicles. Rabbit IgG (eBioscience) or mouse IgG1k (Dako) were used as negative controls and swine anti-rabbit:FITC F(ab´)~2~ (1:300, Dako) or goat anti-mouse:FITC (1:1000, Dako) as the secondary antibodies. All antibodies were diluted in 0.1% sterile-filtered saponin/PBS for detection of toxin within microvesicles. To detect Stx2 on the surface of the microvesicles certain experiments were carried out without saponin.

Acquisition and analysis of microvesicles by flow cytometry {#sec025}
-----------------------------------------------------------

Samples were analyzed using a FACSCanto^TM^II flow cytometer with FACSDiva software version 6.0 (BD Immunocytometry Systems, San Jose, CA) or a CyFlow Cube 8 flow cytometer (Partec, Görlitz, Germany) with FCS Express 4 Flow Research Edition software version 4.07.0003 (De Novo Software, Glendale, CA). Microvesicles were defined by size and positive fluorescence using cell-specific antibodies. Both forward- (FSC) and side scatter (SSC) signals were recorded with logarithmic gain and flow rate was set to low. The microvesicle gate was generated using 0.5, 0.9 and 3.0 μm beads (Megamix beads, BioCytex, Marseille, France) to determine upper limits in both FSC (280) and SSC (340) signals and the lower limits were placed above the background level of the machine and/or buffer which was determined by running 0.2 μm-filtered HBSS.

Single-stained controls were used to check fluorescence compensation settings and fluorescence-minus-one (FMO) was used to define events with fluorescence above background levels to set up positive regions. A microvesicle was defined as an event positive for a specific cell marker and ≤1 μm in size. Microvesicles were quantified as previously described \[[@ppat.1004619.ref027]\].

Cell culture {#sec026}
------------

Conditionally immortalized glomerular cells (CiGEnC) were obtained from Dr. Simon Satchell (Academic Renal Unit, University of Bristol, UK), and cultured as described \[[@ppat.1004619.ref065]\]. CiGEnC were used at passage 26--36. Cells were grown in endothelial growth medium 2---microvascular (EGM2-MV) supplemented with 5% fetal bovine serum and growth factors (all from Lonza, Walkersville, MD) as well as 100 U/mL penicillin and 100 μg/mL streptomycin (PAA Laboratories Gmbh). Cells were grown to 80--90% confluence at 33°C in 5% CO~2~ and then allowed to differentiate for at least five days at 37°C.

Transfer of Stx2-containing microvesicles to glomerular endothelial cells and imaging {#sec027}
-------------------------------------------------------------------------------------

CiGEnC were cultured in T25 culture flasks (TPP AG, Trasadingen, Switzerland) and grown to 90% confluence. The cells were washed with Ca^2+^/Mg^2+^ free HBSS and incubated with Stx2-containing microvesicles isolated from 10 mL whole blood/DMEM. Microvesicles were diluted 1:10 in the cell culture media described above and incubated with the cells for 1, 3, 12 or 24 hours, respectively. Cells were washed with Ca^2+^ /Mg^2+^ free HBSS and detached from the culture flasks using 1x TrypLE^TM^ Select (Life Technology, Carlsbad, CA), washed and fixed in 2.5% glutaraldehyde in 0.15 M sodium-cacodylate buffer (pH 7.9) for 24h. Samples were then dehydrated and prepared for electron microscopy. After overnight polymerization, ultra-thin sections were cut and incubated with polyclonal rabbit anti-Stx2 B-subunit (1:80) and mouse anti-human CD42b (1:80) or mouse anti-human CD45 (1:100). To detect early endosomes or ribosomes samples were incubated with rabbit anti-Rab5 antibody (1:50, Abcam, Cambridge UK) or mouse anti-rRNA Antibody (1:100, Thermo Fisher Scientific Inc., USA), respectively. Samples were then incubated with gold-conjugated goat anti-rabbit IgG:5nm to label Stx or goat anti-mouse IgG:10nm to label platelet or leukocyte microvesicle membranes and goat anti-rabbit IgG:20nm or goat anti-mouse IgG:20nm to label early endosomes or ribosomes, respectively (BBI). Rabbit IgG or mouse IgG (BioLegend) were used as negative controls.

Cytotoxicity assay {#sec028}
------------------

CiGEnC were plated in 96-well plates (Nunc, Roskilde, Denmark) at a density of 1x10^4^ cells/well and incubated as described above. The cells were washed in Ca^2+^/Mg^2+^-free HBSS and pre-incubated with cycloheximide (300 μg/mL, Sigma-Aldrich) in order to enhance protein synthesis-inhibition induced by Shiga toxin, as previously described \[[@ppat.1004619.ref066]\], diluted in EGM2-MV for 3h, washed with HBSS and incubated with microvesicles (2x10^5^/well, diluted in EGM2-MV, the quantity was determined by flow cytometry). Microvesicles were isolated from Stx2- or Stx2 mutant-treated, or untreated whole blood for 36h. All microvesicle samples were washed five times in HBSS. Control samples were treated with Stx2 under two conditions. In the one Stx2 (200 ng/mL, diluted in EGM2-MV) was exposed to washing steps similar to microvesicles before exposure to the cells and in the other cells were exposed to pure Stx2 (200 ng/mL, final concentration diluted in EGM2-MV) without washing steps. Cell viability was determined by crystal violet staining \[[@ppat.1004619.ref067]\] and absorbance measured at 570nm. The effect on cell viability was calculated as the difference in absorbance percentage in the presence or absence of microvesicles. All experiments were performed in triplicate and repeated five times.

Protein synthesis assay {#sec029}
-----------------------

Protein synthesis was determined by assaying the incorporation of \[^35^S\]-methionine into newly synthesized proteins. CiGEnC were grown to 80--90% confluence in 24-well plates (Becton Dickinson, Lincoln Park, NJ) as described above. The cells were washed in Ca^2+^ /Mg^2+^ free HBSS and incubated with cycloheximide for 3 h. Subsequently, the cells were washed and incubated with microvesicles (1 x 10^6^/well, diluted in EGM2-MV) isolated from Stx2-stimulated or unstimulated whole blood, for 36 h, after which the cells were pulsed with \[^35^S\] methionine (50 μCi/mL, PerkinElmer, Waltham, MA), diluted in methionine-free DMEM (Life Technology) for 2 h. After incubation, the cells were washed with Ca^2+^ /Mg^2+^-free HBSS, detached with TrypLe and lysed in a radioimmune precipitation assay (RIPA) buffer (0.15 M NaCl, 30mM HEPES, pH 7.3, 1% Triton-X (v/v), 1% sodium deoxycholate (w/v), and 1% SDS (w/v)) at-20°C for at least one h. Proteins were precipitated with 55% trichloroacetic acid (TCA, Fisher Scientific, Leicestershire, UK), washed with acetone and resuspended in 0.1 M Tric-HCl, pH 8. The proteins were added to liquid scintillation fluid and counted in a liquid scintillation counter. All experiments were done in duplicate and repeated three times (large amounts of blood (\>100 ml/analysis) were required for the microvesicle isolation resulting in three experiments and precluding statistical analysis). Inhibition of protein synthesis was defined as a decrease in the ability of the cells to incorporate \[^35^S\]-methionine divided by total protein.

Statistics {#sec030}
----------

Differences between patients and controls or differences between stimulated and unstimulated samples were assayed by the non-parametrical Mann-Whitney test. All data were analyzed using GraphPadPrism 6.0 (GraphPad Software, Inc., La Jolla, CA). *P* values of ≤0.05 were considered significant.

Ethics statement {#sec031}
----------------

Samples from patients, pediatric controls and healthy donors were taken with the informed written consent of the subjects or their parents. All children had consent given by a parent/guardian as well as their own consent, if over 15 years of age. All adult participants provided their own written informed consent. The study was performed with the approval of the Ethics committee of the Medical Faculty, Lund University (permit \#323-2006).

All animal experiments were approved by the Laboratory Animal Ethics Committee of Lund University (permit \#M391-12) in accordance to guidelines of the Swedish National Board of Agriculture and the EU directive for the protection of animals used for scientific purposes.
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###### Characteristics of patients included in this study.
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###### Identification of blood cell-derived microvesicles in murine plasma.

(DOCX)
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Click here for additional data file.

###### Plaletet counts and blood urea nitrogen in infected mice.

Platelet counts and blood urea nitrogen (BUN) levels in mice infected with *E. coli* O157:H7 strains 86--24 (Shiga toxin 2-producing) or 87--23 (non Shiga toxin-producing) depicted as days after inoculation.

(PPTX)

###### 

Click here for additional data file.

###### Detailed enlargement of microvesicles demonstrated in [Fig. 3](#ppat.1004619.g003){ref-type="fig"} panels I-N.

The upper panels are areas from [Fig. 3 I-N](#ppat.1004619.g003){ref-type="fig"}. Scale bar 100 nm. The lower panels are enlargements of the boxed areas within each of the respective upper panels. Samples were co-incubated with rabbit anti-Stx2 (5 nm, smaller gold conjugates) and rat anti-mouse CD41 (10 nm, detects platelet-derived microvesicles) or rat anti-mouse CD45 (10 nm, detects leukocyte-derived microvesicles, larger gold conjugates).

(TIF)

###### 

Click here for additional data file.
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